The 5 Most Interesting Analyst Questions From Cencora's Q2 Earnings Call

Cencora’s third quarter results outperformed Wall Street’s expectations on both revenue and adjusted profit, but the market reacted negatively, reflecting investor concerns about slower growth in key areas. Management attributed the quarter’s outcomes to continued strength in U.S. Healthcare Solutions, particularly specialty distribution and higher utilization of pharmaceuticals, including GLP-1 products. However, CEO Robert Mauch and CFO James Cleary acknowledged moderating growth in GLP-1s and biosimilars, and highlighted the impact of losing a large, low-margin grocery customer. Cleary also flagged persistent weakness in the international segment, especially in global specialty logistics and consulting, where a sluggish biotech funding environment and subdued clinical trial activity weighed on results.

Is now the time to buy COR? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions From Cencora’s Q2 Earnings Call

• Lisa Gill (JPMorgan) asked about drivers of U.S. segment growth moderation and international headwinds. CFO James Cleary explained that biosimilar adoption and slower GLP-1 growth impacted revenue, while international weakness was tied to subdued biotech activity.
• Elizabeth Anderson (Evercore ISI) inquired about RCA integration and policy risk. CEO Robert Mauch described strong cultural fit and customer acceptance, but noted ongoing uncertainty around drug pricing policy and its impact on reimbursement.
• Michael Cherny (Leerink Partners) asked about factors influencing next year’s growth relative to long-term targets. Cleary cited ongoing RCA contribution, loss of an oncology customer, and possible improvement in international trends as key variables.
• Eric Percher (Nephron Research) focused on tariff exposure and inflation. Cleary and Mauch said current tariffs have not materially affected Cencora, but highlighted ongoing monitoring for potential supply chain and patient access risks.
• Erin Wright (Morgan Stanley) questioned the company’s approach to resource allocation and strategic fit in underperforming businesses. Mauch confirmed a rigorous portfolio review, with investments being shifted toward high-growth, strategically aligned segments.

Catalysts in Upcoming Quarters

In the coming quarters, our analysts will track (1) the pace of specialty growth within the U.S. Healthcare Solutions segment, particularly contributions from recently acquired RCA, (2) the trajectory of international segment recovery as biotech funding and clinical trial activity evolve, and (3) the impact of regulatory changes, including tariffs and drug pricing reforms, on both revenue and supply chain resilience. The effectiveness of Cencora’s digital transformation and portfolio review initiatives will also be important signposts for future performance.

Cencora currently trades at $288, down from $292.32 just before the earnings. Is the company at an inflection point that warrants a buy or sell? Find out in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

Trump’s April 2025 tariff bombshell triggered a massive market selloff, but stocks have since staged an impressive recovery, leaving those who panic sold on the sidelines.

Take advantage of the rebound by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.

StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.